Sage Therapeutics (NASDAQ:SAGE) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Sage ...

Across the recent three months, 14 analysts have shared their insights on Sage Therapeutics (NASDAQ:SAGE), expressing a variety of opinions spanning from bullish to bearish. In the table below ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Its main asset is Zurzuvae, which is co-marketed with Biogen for PPD. BIIB recently made a bid ...

Good afternoon. Welcome to Sage Therapeutics First Quarter 2025 Financial Results Conference Call. [Operator Instructions] This call is being webcast live on the Investors and Media section of ...

Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Hold rating on SAGE Therapeutics (SAGE – Research Report). The associated price target remains the same with $25.00. Douglas Tsao ...

SAGE Therapeutics (SAGE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao from H.C. Wainwright reiterated a Hold rating on the ...

Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading for the exits along with a swath of the company's leadership.

The latest price target for Sage Therapeutics (NASDAQ:SAGE) was reported by Needham on April 30, 2025. The analyst firm set a price target for $0.00 expecting SAGE to fall to within 12 months (a ...